Plain-English translation of NCT07302607 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study that looks backward at medical records from patients with advanced melanoma who received immunotherapy treatment (medications that help your immune system fight cancer, specifically anti-PD-1 and/or anti-CTLA-4 drugs). The researchers want to understand which patients had complete and lasting responses to this medication, and what factors — beyond those already known — might predict who will benefit most.
While this medication has helped many melanoma patients, not everyone responds equally well or experiences long-lasting improvement. By studying past patients' records, researchers hope to discover new clues about what makes some people more likely to have a complete response to the treatment, which could help doctors predict outcomes and personalize care for future patients.
You likely qualify if…
You likely don't qualify if…
This is not an active treatment study — you would not receive any medication or participate in visits. Instead, researchers would review your existing medical records from your past immunotherapy treatment between 2013 and 2021, including information about your cancer response, test results, and follow-up appointments. The study team would analyze this data to identify patterns and factors that may have predicted which patients benefited most from the treatment.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
France
Sponsor
University Hospital, Strasbourg, France
Enrollment target
~221 participants
Started
December 2024
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Cédric LENORMAND, MD
University Hospital, Strasbourg, France
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.